Cardiovascular CRO Services

These programs often involve living or genetically modified products, tightly coordinated handling and logistics, acute safety risks, and extended long-term follow-up obligations. Sponsors may be managing collection, manufacturing, shipping, infusion, monitoring, and post-treatment surveillance in one program, which creates more operational interdependence than many other oncology trials.

Worldwide supports oncology cell therapy studies with tailored logistics planning, detailed handling procedures, and close coordination across sites, vendors, and study teams. This includes attention to chain of custody, chain of identity, chain of condition, along with operational controls needed to ensure patient-specific products move through each step as planned.

Worldwide supports sponsors with execution built around high-acuity monitoring and fast coordination if serious events occur. For cell therapy studies, that includes planning around CRS, ICANS, TLS, hospitalization workflows, and the communication needs that come with time-sensitive safety oversight.

Worldwide supports both autologous and allogeneic cell therapy programs globally across hematologic malignancies and solid tumors. This experience helps sponsors to work with teams who understand how product flow, site readiness, patient timing, and operational complexity can vary between approaches.

Yes. Long-term follow-up is a core component of cell and gene therapy development. Worldwide supports sponsors with planning and execution that account for the operational, safety, and resourcing demands that extend well beyond the initial treatment.

While this page largely focuses on oncology cell therapy, a reflection of historical trends in oncology CGT development, Worldwide also has experience with viral-vectored gene therapy, oncolytic viruses, and other genetic medicine modalities of oncology development. This is a rapidly evolving space — we understand the complexities of regulatory planning, product handling, safety oversight across modalities. Sponsors looking for broader modality detail can also explore Worldwide’s Cell and Gene Therapy expertise.

With sites across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa, Worldwide helps sponsors identify sites equipped for the realities of oncology cell and gene therapy studies, including handling requirements, safety protocols, and specialized operational workflows. That support helps sponsors plan around feasibility, readiness, and execution risk early in the study.